Company profile
Employees
Incorporated
Location
Fiscal year end
SEC CIK
IRS number
813931841
Latest filings (excl ownership)
Latest ownership filings
Institutional ownership, Q1 2024
18.8% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 7 |
Opened positions | 2 |
Closed positions | 4 |
Increased positions | 0 |
Reduced positions | 1 |
13F shares | Current |
---|---|
Total value | 59.05 mm |
Total shares | 40.77 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
BMY Bristol-Myers Squibb | 11.95 mm | $0.00 |
Dragasac | 8.59 mm | $49.71 mm |
UTHR United Therapeutics | 7.97 mm | $0.00 |
Human Longevity | 7.01 mm | $0.00 |
SRNEQ Sorrento Therapeutics | 5.05 mm | $1.12 mm |
Context Capital Management | 150.00 k | $6.17 mm |
Emfo | 50.00 k | $2.06 mm |
Proequities | 0.00 | $0.00 |
Press releases
Celularity Presents Data of The Effect of Its T-Cell Platform on Multiple Hematological And Solid Tumors at the American Society of Clinical Oncology (ASCO) Annual Meeting
3 Jun 24
Celularity Inc. Announces Receipt of Nasdaq Notice Regarding Late Form 10-Q Filing
24 May 24
Celularity Data Published in Journal for ImmunoTherapy of Cancer Reveals Benefits of Placental Circulating T Cells for CAR-T Therapy
14 May 24